Company Overview
Origin Agritech Limited operates within the People's Republic of China as a specialized entity focused on agricultural biotechnology, specifically engaging in the development, production, and distribution of hybrid crop seeds alongside the advancement of hybrid seed technology. The company is categorized within the Basic Materials sector and the Agricultural Inputs industry, positioning it as a provider of essential biological resources for the agricultural supply chain. With a market capitalization of $17.59M and an annual revenue of $91.29M, the firm maintains a workforce of 97 employees, reflecting a lean operational structure typical of biotechnology firms in early growth or development phases. The relatively modest market cap combined with revenue exceeding $90 million suggests a capital-light business model where significant revenue generation is achieved with a small employee base, yet the valuation metrics indicate that market participants are pricing the company based on future potential rather than current profitability, as evidenced by the negative price-to-book ratio of -5.12.
Financial Health
The company reported total revenue of $91.29M over the trailing twelve months, yet recorded a net income of $-53,328,000 and an EBITDA of $-50,603,000, revealing a substantial disconnect between top-line sales and bottom-line profitability. This significant gap between revenue and net income indicates a cost structure where operating expenses, likely driven by research and development in hybrid seed technology, far exceed gross profits, resulting in an operating margin of -153.8%. The gross margin stands at 7.0%, which suggests that the cost of goods sold consumes the majority of sales revenue before operating expenses are deducted, while the profit margin of -58.4% confirms that the company is burning cash on every dollar of revenue generated. Free cash flow for the period was $-23,485,876, indicating a negative cash generation capability that limits the company's immediate financial flexibility and reliance on external capital sources. On the balance sheet, the company holds $15.88M in cash against $44.96M in debt, creating a net debt position that requires careful management of refinancing or equity issuance. Although the debt-to-equity ratio is listed as N/A due to the negative equity, the current ratio of 0.44 signals that current assets are less than half of current liabilities, highlighting potential short-term liquidity challenges. Furthermore, the return on equity is N/A given the negative equity position, while the return on assets is -29.0%, demonstrating that management is currently destroying value relative to the asset base rather than generating returns for shareholders.
Valuation Assessment
The trailing twelve-month P/E ratio and forward P/E ratio are both N/A because the company is reporting net losses, making traditional earnings-based valuation metrics inapplicable. In the absence of positive earnings, the price-to-book ratio of -5.12 indicates that the market is valuing the company at less than the book value of its assets, or that the equity value is negative, which is a common characteristic of unprofitable biotechnology firms awaiting breakthroughs. The price-to-sales ratio of 0.19 and the EV/EBITDA of -0.16 serve as alternative valuation metrics that suggest the market is assigning a very low multiple to its revenue, reflecting high risk and uncertainty regarding future profitability. Regarding trading ranges, the stock has a 52-week high of $2.49 and a 52-week low of $0.74; without a specific current price provided in the facts, the valuation context is strictly defined by these historical bounds and the negative earnings multiples. The beta of 1.86 indicates that the stock's price volatility is significantly higher than the broader market, moving nearly twice as much as the index in either direction, which amplifies risk for position holders during periods of market stress.
Growth & Income
Revenue growth year-over-year declined by 11.2%, while earnings growth is N/A due to the company's persistent net losses, meaning earnings are not growing faster than revenue but rather contracting alongside a shrinking top line. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that all available cash flow is being retained to fund operations and research rather than being distributed to shareholders. This reinvestment strategy is typical for agricultural biotechnology firms that prioritize developing new hybrid seed technologies over returning capital to investors. Overall, the growth and income profile is characterized by negative revenue momentum and a complete lack of dividend income, leaving investors reliant on potential future valuation expansion driven by eventual profitability or a successful commercialization of new products.